Dual human antibodies stop lethal Nipah and Hendra even after infection begins

AI Summary

Researchers at the Icahn School of Medicine at Mount Sinai have developed a fully human monoclonal antibody cocktail that provides complete protection against lethal Nipah and Hendra virus infections, even when treatment starts post-infection. This breakthrough offers a new therapeutic avenue for managing these deadly viruses.

An international research team led by investigators in the Department of Microbiology at the Icahn School of Medicine at Mount Sinai has developed the first fully human monoclonal antibody cocktail shown to provide complete protection against lethal Nipah and Hendra virus infection. The protection was seen even when treatment was given after infection had begun.